A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

Yoshimura, Kazuhiro; Minami, Takafumi; Nozawa, Masahiro; Kimura, Takahiro; Egawa, Shin; Fujimoto, Hiroyuki; Yamada, Akira; Itoh, Kyogo; Uemura, Hirotsugu

doi:10.1016/j.eururo.2015.12.050

Cited by 71 publications

(79 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its immunosuppressive effects dexamethasone is generally thought to be difficult to combine with therapeutic vaccination; however, interestingly, dexamethasone seems to increase Bcl-2 dependence in MM resulting in increased sensitivity to the Bcl-2-inhibitor venetoclax in vitro (14). Furthermore, a recent paper reported the efficacy of a peptide vaccine combined with low-dose dexamethasone in prostate cancer (15). This is interesting when considering future trials of peptide vaccinations in MM, since most MM treatments contain dexamethasone.…”

mentioning

confidence: 99%

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial

Jørgensen

Ahmad

Abildgaard

et al. 2016

Stem Cell Investig.

View full text Add to dashboard Cite

mentioning

confidence: 99%

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial

Jørgensen

Ahmad

Abildgaard

et al. 2016

Stem Cell Investig.

View full text Add to dashboard Cite

“…A series of early phase (phase I and/or phase II) clinical trials of PPV that were conducted for patients with various types of advanced cancers, including CRC, have shown the feasibility of this new approach [69][70][71][72][73][74][75][76][77][78][79][80]. For example, we have recently demonstrated that the patients treated with PPV showed a significantly longer overall survival (OS) than those with standard care and treatment in randomized phase II studies for bladder cancer and prostate cancer [72,73].…”

Section: Rationale Of Ppvmentioning

confidence: 99%

Personalized immunotherapy in colorectal cancer

Ohtake

Wada

Yada

et al. 2016

Expert Review of Precision Medicine and Drug Development

Self Cite

View full text Add to dashboard Cite

The fields of cancer immunology and immunotherapy have made dramatic progress in the past 20 years. Various approaches to cancer immunotherapies, including cancer vaccines using peptides, proteins, DNA, and dendritic cells, have been developed to activate antigen-specific immune cells and their efficacy has been clinically examined. Herein, we summarize previously performed clinical trials of various immunotherapies against colorectal cancer (CRC), including our own novel immunotherapeutic approach, the "personalized peptide vaccine", in which human leukocyte antigen (HLA)-matched vaccine peptides are selected based on pre-existing host immunity before vaccination. In the near future, neoepitopes identified through massive DNA sequencing of the genetic alterations in tumor cells, combined with robust T cell epitope predictions in each patient might be targeted as a personalized immunotherapy for CRC. ARTICLE HISTORY

show abstract

“…In a randomized phase 2 study, the combination treatment of PPV with low‐dose EMP for CRPC patients showed a longer survival than that of standard dose EMP . Another combination treatment of PPV with low‐dose dexamethasone for patients with chemotherapy‐naïve CRPC also showed longer PSA progression‐free survival and median survival time . In addition, another phase 2 study suggested that the OS of docetaxel‐resistant CRPC patients treated with PPV ( n = 20) was longer than that of historical controls ( n = 17) (17.8 months vs 10.5 months, P = 0.166) .…”

Section: Cancer Vaccinesmentioning

confidence: 99%

Clinical development of immunotherapy for prostate cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Prostate cancer is the most common cancer in men, and the second leading cause of cancer-related death in Western countries. Prostate cancer-related death occurs in patients with metastatic castration-resistant prostate cancer. Although several new drugs for castration-resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed.

show abstract

A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

Abstract: UMIN-CTR: 000000959.

Cited by 71 publications

References 28 publications

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial

Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial

Personalized immunotherapy in colorectal cancer

Clinical development of immunotherapy for prostate cancer

Contact Info

Product

Resources

About